In all classical AIS individuals (genetically proven AIS, group 3) previously identified by Sanger sequencing, mutations in the AR-CDS could be validated by our custom NGS AR panel, underlining the validity of the NGS approach. This evidence concerns the gene AR and androgen insensitivity syndrome.